Pharmacogenomics of response to statin treatment and susceptibility to statin-induced adverse drug reactions in Asians: a scoping review

[1] Ginsberg HN. Review: efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab. 2006; 91:383–92. GinsbergHN Review: efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia J Clin Endocrinol Metab 2006 91 383 92 Search in Google Scholar

[2] Prospective Studies Collaboration; Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007; 370:1829–39. Prospective Studies Collaboration LewingtonS WhitlockG ClarkeR SherlikerP EmbersonJ Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths Lancet 2007 370 1829 39 Search in Google Scholar

[3] Emerging Risk Factors Collaboration; Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009; 302:1993–2000. Emerging Risk Factors Collaboration Di AngelantonioE SarwarN PerryP KaptogeS RayKK Major lipids, apolipoproteins, and risk of vascular disease JAMA 2009 302 1993 2000 Search in Google Scholar

[4] Barter PJ. High-versus low-dose statin: effects on cardiovascular events and all-cause death. Circulation. 2018; 137:2013–5. BarterPJ High-versus low-dose statin: effects on cardiovascular events and all-cause death Circulation 2018 137 2013 5 Search in Google Scholar

[5] Olsson AG, McTaggart F, Raza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev. 2002; 20:303–28. OlssonAG McTaggartF RazaA Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor Cardiovasc Drug Rev 2002 20 303 28 Search in Google Scholar

[6] Naito R, Miyauchi K, Daida H. Racial differences in the cholesterol-lowering effect of statin. J Atheroscler Thromb. 2017; 24:19–25. NaitoR MiyauchiK DaidaH Racial differences in the cholesterol-lowering effect of statin J Atheroscler Thromb 2017 24 19 25 Search in Google Scholar

[7] Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018; 169:467–73. TriccoAC LillieE ZarinW O’BrienKK ColquhounH LevacD PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation Ann Intern Med 2018 169 467 73 Search in Google Scholar

[8] Whirl-Carrillo M, McDonagh EM, Hebert JM, Sangkuhl GK, Thorn CF, Altman RB, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012; 92:414–7. Whirl-CarrilloM McDonaghEM HebertJM SangkuhlGK ThornCF AltmanRB Pharmacogenomics knowledge for personalized medicine Clin Pharmacol Ther 2012 92 414 7 Search in Google Scholar

[9] Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics. 2008; 9:19–33. PasanenMK NeuvonenPJ NiemiM Global analysis of genetic variation in SLCO1B1 Pharmacogenomics 2008 9 19 33 Search in Google Scholar

[10] Kaewboonlert N, Thitisopee W, Sirintronsopon W, Porntadavity S, Jeenduang N. Lack of association between SLCO1B1 polymorphisms and lipid-lowering response to simvastatin therapy in Thai hypercholesterolaemic patients. J Clin Pharm Ther. 2018; 43:647–55. KaewboonlertN ThitisopeeW SirintronsoponW PorntadavityS JeenduangN Lack of association between SLCO1B1 polymorphisms and lipid-lowering response to simvastatin therapy in Thai hypercholesterolaemic patients J Clin Pharm Ther 2018 43 647 55 Search in Google Scholar

[11] Lee HK, Hu M, Lui S, Ho CS, Wong CK, Tomlinson B. Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients. Pharmacogenomics. 2013; 14:1283–94. LeeHK HuM LuiS HoCS WongCK TomlinsonB Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients Pharmacogenomics 2013 14 1283 94 Search in Google Scholar

[12] Hu M, Mak VWL, Tomlinson B. Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia. Pharmacogenet Genomics. 2012; 22:803–6. HuM MakVWL TomlinsonB Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia Pharmacogenet Genomics 2012 22 803 6 Search in Google Scholar

[13] Birmingham BK, Bujac SR, Elsby R, Azumaya CT, Zalikowski J, Chen Y, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States. Eur J Clin Pharmacol. 2015; 71:329–40. BirminghamBK BujacSR ElsbyR AzumayaCT ZalikowskiJ ChenY Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States Eur J Clin Pharmacol 2015 71 329 40 Search in Google Scholar

[14] Kadam P, Ashavaid TF, Ponde CK, Rajani RM. Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population. J Clin Pharm Ther. 2016; 41:329–33. KadamP AshavaidTF PondeCK RajaniRM Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population J Clin Pharm Ther 2016 41 329 33 Search in Google Scholar

[15] Donnelly LA, Doney ASF, Tavendale R, Lang CC, Pearson ER, Colhoun HM, et al. Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. Clin Pharmacol Ther. 2011; 89:210–6. DonnellyLA DoneyASF TavendaleR LangCC PearsonER ColhounHM Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study Clin Pharmacol Ther 2011 89 210 6 Search in Google Scholar

[16] Mangravite LM, Thorn CF, Krauss RM. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J. 2006; 6:360–74. MangraviteLM ThornCF KraussRM Clinical implications of pharmacogenomics of statin treatment Pharmacogenomics J 2006 6 360 74 Search in Google Scholar

[17] Liu N, Yang G, Hu M, Cai Y, Hu Z, Jia C, et al. Association of ABCC2 polymorphism and gender with high-density lipoprotein cholesterol response to simvastatin. Pharmacogenomics. 2018; 19:1125–32. LiuN YangG HuM CaiY HuZ JiaC Association of ABCC2 polymorphism and gender with high-density lipoprotein cholesterol response to simvastatin Pharmacogenomics 2018 19 1125 32 Search in Google Scholar

[18] Renjie Z. The influence of gene mutation to statin responsiveness on high-risk CVD population in Chinese. Heart. 2012; 98(Suppl 2): E50. doi: 10.1136/heartjnl-2012-302920a.122 RenjieZ The influence of gene mutation to statin responsiveness on high-risk CVD population in Chinese Heart 2012 98 Suppl 2 E50 10.1136/heartjnl-2012-302920a.122 Open DOISearch in Google Scholar

[19] Schmitz G, Langmann T, Heimerl S. Role of ABCG1 and other ABCG family members in lipid metabolism. J Lipid Res. 2001; 42:1513–20. SchmitzG LangmannT HeimerlS Role of ABCG1 and other ABCG family members in lipid metabolism J Lipid Res 2001 42 1513 20 Search in Google Scholar

[20] Hu M, Lui SS, Mak VW, Chu TT, Lee VW, Poon EW, et al. Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients. Pharmacogenet Genomics. 2010; 20:634–7. HuM LuiSS MakVW ChuTT LeeVW PoonEW Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients Pharmacogenet Genomics 2010 20 634 7 Search in Google Scholar

[21] Tomlinson B, Hu M, Lee VW, Lui SS, Chu TT, Poon EW, et al. ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther. 2010; 87:558–62. TomlinsonB HuM LeeVW LuiSS ChuTT PoonEW ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin Clin Pharmacol Ther 2010 87 558 62 Search in Google Scholar

[22] Jiang XY, Zhang Q, Chen P, Li SY, Zhang NN, Chen XD, et al. CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin. J Clin Pharm Ther. 2012; 37:719–23. JiangXY ZhangQ ChenP LiSY ZhangNN ChenXD CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin J Clin Pharm Ther 2012 37 719 23 Search in Google Scholar

[23] Wei KK, Zhang LR, Zhang Y, Hu XJ. Interactions between CYP7A1 A-204C and ABCG8 C1199A polymorphisms on lipid lowering with atorvastatin. J Clin Pharm Ther. 2011; 36:725–33. WeiKK ZhangLR ZhangY HuXJ Interactions between CYP7A1 A-204C and ABCG8 C1199A polymorphisms on lipid lowering with atorvastatin J Clin Pharm Ther 2011 36 725 33 Search in Google Scholar

[24] Chien KL, Wang KC, Chen YC, Chao CL, Hsu HC, Chen MF, et al. Common sequence variants in pharmacodynamic and pharmacokinetic pathway-related genes conferring LDL cholesterol response to statins. Pharmacogenomics. 2010; 11:309–17. ChienKL WangKC ChenYC ChaoCL HsuHC ChenMF Common sequence variants in pharmacodynamic and pharmacokinetic pathway-related genes conferring LDL cholesterol response to statins Pharmacogenomics 2010 11 309 17 Search in Google Scholar

[25] Srivastava A, Garg N, Srivastava A, Srivastava K, Mittal B. Effect of genetic variant (rs11887534) in ABCG8 gene in coronary artery disease and response to atorvastatin therapy. Dis Markers. 2010; 28:307–13. SrivastavaA GargN SrivastavaA SrivastavaK MittalB Effect of genetic variant (rs11887534) in ABCG8 gene in coronary artery disease and response to atorvastatin therapy Dis Markers 2010 28 307 13 Search in Google Scholar

[26] Li J, Wang LF, Li ZQ, Pan W. Effect of R219K polymorphism of the ABCA1 gene on the lipid-lowering effect of pravastatin in Chinese patients with coronary heart disease. Clin Exp Pharmacol Physiol. 2009; 36:567–70. LiJ WangLF LiZQ PanW Effect of R219K polymorphism of the ABCA1 gene on the lipid-lowering effect of pravastatin in Chinese patients with coronary heart disease Clin Exp Pharmacol Physiol 2009 36 567 70 Search in Google Scholar

[27] Maxwell WD, Ramsey LB, Johnson SG, Moore KG, Shtutman M, Schoonover JH, et al. Impact of pharmacogenetics on efficacy and safety of statin therapy for dyslipidemia. Pharmacotherapy. 2017; 37:1172–90. MaxwellWD RamseyLB JohnsonSG MooreKG ShtutmanM SchoonoverJH Impact of pharmacogenetics on efficacy and safety of statin therapy for dyslipidemia Pharmacotherapy 2017 37 1172 90 Search in Google Scholar

[28] Vermes A, Vermes I. Genetic polymorphisms in cytochrome P450 enzymes. Am J Cardiovasc Drugs. 2004; 4:247–55. VermesA VermesI Genetic polymorphisms in cytochrome P450 enzymes Am J Cardiovasc Drugs 2004 4 247 55 Search in Google Scholar

[29] Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther. 2017; 102:688–700. ZhouY Ingelman-SundbergM LauschkeVM Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects Clin Pharmacol Ther 2017 102 688 700 Search in Google Scholar

[30] Hu M, Mak VW, Xiao Y, Tomlinson B. Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia. Pharmacogenomics. 2013; 14:25–34. HuM MakVW XiaoY TomlinsonB Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia Pharmacogenomics 2013 14 25 34 Search in Google Scholar

[31] Gao Y, Zhang LR, Fu Q. CYP3A4^*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. Eur J Clin Pharmacol. 2008; 64:877–82. GaoY ZhangLR FuQ CYP3A4^*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin Eur J Clin Pharmacol 2008 64 877 82 Search in Google Scholar

[32] Peng C, Ding Y, Yi X, Shen Y, Dong Z, Cao L, et al. Polymorphisms in CYP450 genes and the therapeutic effect of atorvastatin on ischemic stroke: a retrospective cohort study in Chinese population. Clin Ther. 2018; 40:469–77.e2. PengC DingY YiX ShenY DongZ CaoL Polymorphisms in CYP450 genes and the therapeutic effect of atorvastatin on ischemic stroke: a retrospective cohort study in Chinese population Clin Ther 2018 40 469 77.e2 Search in Google Scholar

[33] Lin J, Zhang Y, Zhou H, Wang X, Wang W. CYP2C9 genetic polymorphism is a potential predictive marker for the efficacy of rosuvastatin therapy. Clin Lab. 2015; 61:1317–24. LinJ ZhangY ZhouH WangX WangW CYP2C9 genetic polymorphism is a potential predictive marker for the efficacy of rosuvastatin therapy Clin Lab 2015 61 1317 24 Search in Google Scholar

[34] Finkelman RD, Wang TD, Wang Y, Azumaya CT, Birmingham BK, Wissmar J, et al. Effect of CYP2C19 polymorphism on the pharmacokinetics of rosuvastatin in healthy Taiwanese subjects. Clin Pharmacol Drug Dev. 2015; 4:33–40. FinkelmanRD WangTD WangY AzumayaCT BirminghamBK WissmarJ Effect of CYP2C19 polymorphism on the pharmacokinetics of rosuvastatin in healthy Taiwanese subjects Clin Pharmacol Drug Dev 2015 4 33 40 Search in Google Scholar

[35] Li J, Wang X, Zhang Z, Zou J, Chen Y, Wang X, et al. Statin therapy correlated CYP2D6 gene polymorphism and hyperlipidemia. Curr Med Res Opin. 2014; 30:223–8. LiJ WangX ZhangZ ZouJ ChenY WangX Statin therapy correlated CYP2D6 gene polymorphism and hyperlipidemia Curr Med Res Opin 2014 30 223 8 Search in Google Scholar

[36] Wei KK, Zhang LR. Interactions between CYP3A5^*3 and POR^*28 polymorphisms and lipid lowering response with atorvastatin. Clin Drug Investig. 2015; 35:583–91. WeiKK ZhangLR Interactions between CYP3A5^*3 and POR^*28 polymorphisms and lipid lowering response with atorvastatin Clin Drug Investig 2015 35 583 91 Search in Google Scholar

[37] Li YP, Zhang LR, Jia M, Hu XJ. CYP3AP1^*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women. J Clin Pharmacol. 2011; 51:181–8. LiYP ZhangLR JiaM HuXJ CYP3AP1^*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women J Clin Pharmacol 2011 51 181 8 Search in Google Scholar

[38] Pandey AV, Sproll P. Pharmacogenomics of human P450 oxidoreductase. Front Pharmacol. 2014; 5:103. doi: 10.3389/fphar.2014.00103 PandeyAV SprollP Pharmacogenomics of human P450 oxidoreductase Front Pharmacol 2014 5 103 10.3389/fphar.2014.00103 Open DOISearch in Google Scholar

[39] Mahley RW, Innerarity TL, Rall SC Jr, Weisgraber KH. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res. 1984; 25:1277–94. MahleyRW InnerarityTL RallSCJr WeisgraberKH Plasma lipoproteins: apolipoprotein structure and function J Lipid Res 1984 25 1277 94 Search in Google Scholar

[40] Wong K, Ryan RO. Characterization of apolipoprotein AV structure and mode of plasma triacylglycerol regulation. Curr Opin Lipidol. 2007; 18:319–24. WongK RyanRO Characterization of apolipoprotein AV structure and mode of plasma triacylglycerol regulation Curr Opin Lipidol 2007 18 319 24 Search in Google Scholar

[41] Baum L, Tomlinson B, Thomas GN. APOA5-1131T>C polymorphism is associated with triglyceride levels in Chinese men. Clin Genet. 2003; 63:377–9. BaumL TomlinsonB ThomasGN APOA5-1131T>C polymorphism is associated with triglyceride levels in Chinese men Clin Genet 2003 63 377 9 Search in Google Scholar

[42] Hubacek JA, Lánská V, Škodová Z, Adámková V, Poledne R. Sex-specific interaction between APOE and APOA5 variants and determination of plasma lipid levels. Eur J Hum Genet. 2008; 16:135–8. HubacekJA LánskáV ŠkodováZ AdámkováV PoledneR Sex-specific interaction between APOE and APOA5 variants and determination of plasma lipid levels Eur J Hum Genet 2008 16 135 8 Search in Google Scholar

[43] Son KY, Son H-Y, Chae J, Hwang J, Jang S, Yun JM, et al. Genetic association of APOA5 and APOE with metabolic syndrome and their interaction with health-related behavior in Korean men. Lipids Health Dis. 2015; 14:1–9. SonKY SonH-Y ChaeJ HwangJ JangS YunJM Genetic association of APOA5 and APOE with metabolic syndrome and their interaction with health-related behavior in Korean men Lipids Health Dis 2015 14 1 9 Search in Google Scholar

[44] Hua S, Ma C, Zhang J, Li J, Wu W, Xu N, et al. Influence of APOA5 locus on the treatment efficacy of three statins: evidence from a randomized pilot study in Chinese subjects. Front Pharmacol. 2018; 9:352. doi: 10.3389/fphar.2018.00352 HuaS MaC ZhangJ LiJ WuW XuN Influence of APOA5 locus on the treatment efficacy of three statins: evidence from a randomized pilot study in Chinese subjects Front Pharmacol 2018 9 352 10.3389/fphar.2018.00352 Open DOISearch in Google Scholar

[45] Hu M, Mak VWL, Tomlinson B. Polymorphisms in apolipoprotein E and apolipoprotein AV do not influence the lipid response to rosuvastatin but are associated with baseline lipid levels in Chinese patients with hyperlipidemia. J Clin Lipidol. 2012; 6:585–92. HuM MakVWL TomlinsonB Polymorphisms in apolipoprotein E and apolipoprotein AV do not influence the lipid response to rosuvastatin but are associated with baseline lipid levels in Chinese patients with hyperlipidemia J Clin Lipidol 2012 6 585 92 Search in Google Scholar

[46] Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. J Lipid Res. 2009; 50:S183–8. MahleyRW WeisgraberKH HuangY Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS J Lipid Res 2009 50 S183 8 Search in Google Scholar

[47] Wanmasae S, Sirintronsopon W, Porntadavity S, Jeenduang N. The effect of APOE, CETP, and PCSK9 polymorphisms on simvastatin response in Thai hypercholesterolemic patients. Cardiovasc Ther. 2017; 35:e12302. doi: 10.1111/1755-5922.12302 WanmasaeS SirintronsoponW PorntadavityS JeenduangN The effect of APOE, CETP, and PCSK9 polymorphisms on simvastatin response in Thai hypercholesterolemic patients Cardiovasc Ther 2017 35 e12302 10.1111/1755-5922.12302 Open DOISearch in Google Scholar

[48] Liu TN, Wu CT, He F, Yuan W, Li SX, Li HW, et al. Relationship between the G75A polymorphism in the apolipoprotein A1 (ApoA1) gene and the lipid regulatory effects of pravastatin in patients with hyperlipidemia. Genet Mol Res. 2016; 15:1–6. LiuTN WuCT HeF YuanW LiSX LiHW Relationship between the G75A polymorphism in the apolipoprotein A1 (ApoA1) gene and the lipid regulatory effects of pravastatin in patients with hyperlipidemia Genet Mol Res 2016 15 1 6 Search in Google Scholar

[49] Medina MW, Krauss RM. The role of HMGCR alternative splicing in statin efficacy. Trends Cardiovasc Med. 2009; 19:173–7. MedinaMW KraussRM The role of HMGCR alternative splicing in statin efficacy Trends Cardiovasc Med 2009 19 173 7 Search in Google Scholar

[50] Chung JY, Cho SK, Oh ES, Lee DH, Lim LA, Jang SB, et al. Effect of HMGCR variant alleles on low-density lipoprotein cholesterol – lowering response to atorvastatin in healthy Korean Subjects. J Clin Pharmacol. 2012; 52:339–46. ChungJY ChoSK OhES LeeDH LimLA JangSB Effect of HMGCR variant alleles on low-density lipoprotein cholesterol – lowering response to atorvastatin in healthy Korean Subjects J Clin Pharmacol 2012 52 339 46 Search in Google Scholar

[51] Poirier S, Mayer G, Poupon V, McPherson PS, Desjardins R, Ly K, et al. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J Biol Chem. 2009; 284:28856–64. PoirierS MayerG PouponV McPhersonPS DesjardinsR LyK Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route J Biol Chem 2009 284 28856 64 Search in Google Scholar

[52] Hubacek JA, Bobkova D. Role of cholesterol 7α-hydroxylase (CYP7A1) in nutrigenetics and pharmacogenetics of cholesterol lowering. Mol Diagn Ther. 2006; 10:93–100. HubacekJA BobkovaD Role of cholesterol 7α-hydroxylase (CYP7A1) in nutrigenetics and pharmacogenetics of cholesterol lowering Mol Diagn Ther 2006 10 93 100 Search in Google Scholar

[53] Liu N, Yang G, Liu Y, Hu M, Cai Y, Hu Z, et al. Effect of cytochrome P450 7A1 (CYP7A1) polymorphism on lipid responses to simvastatin treatment. J Cardiovasc Pharmacol. 2020; 75:168–73. LiuN YangG LiuY HuM CaiY HuZ Effect of cytochrome P450 7A1 (CYP7A1) polymorphism on lipid responses to simvastatin treatment J Cardiovasc Pharmacol 2020 75 168 73 Search in Google Scholar

[54] Kondo I, Berg K, Drayna D, Lawn R. DNA polymorphism at the locus for human cholesteryl ester transfer protein (CETP) is associated with high density lipoprotein cholesterol and apolipoprotein levels. Clin Genet. 1989; 35:49–56. KondoI BergK DraynaD LawnR DNA polymorphism at the locus for human cholesteryl ester transfer protein (CETP) is associated with high density lipoprotein cholesterol and apolipoprotein levels Clin Genet 1989 35 49 56 Search in Google Scholar

[55] Kuivenhoven JA, de Knijff P, Boer JMA, Smalheer HA, Botma G-J, Seidell JC, et al. Heterogeneity at the CETP gene locus: influence on plasma CETP concentrations and HDL cholesterol levels. Arterioscler Thromb Vasc Biol. 1997; 17:560–8. KuivenhovenJA de KnijffP BoerJMA SmalheerHA BotmaG-J SeidellJC Heterogeneity at the CETP gene locus: influence on plasma CETP concentrations and HDL cholesterol levels Arterioscler Thromb Vasc Biol 1997 17 560 8 Search in Google Scholar

[56] Liu S, Schmitz C, Stampfer MJ, Sacks F, Hennekens CH, Lindpaintner K, et al. A prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men. Atherosclerosis. 2002; 161:469–74. LiuS SchmitzC StampferMJ SacksF HennekensCH LindpaintnerK A prospective study of TaqIB polymorphism in the gene coding for cholesteryl ester transfer protein and risk of myocardial infarction in middle-aged men Atherosclerosis 2002 161 469 74 Search in Google Scholar

[57] Mead JR, Irvine SA, Ramji DP. Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med. 2002; 80:753–69. MeadJR IrvineSA RamjiDP Lipoprotein lipase: structure, function, regulation, and role in disease J Mol Med 2002 80 753 69 Search in Google Scholar

[58] Jonas A. Lecithin cholesterol acyltransferase. Biochim Biophys Acta. 2000; 1529:245–56. JonasA Lecithin cholesterol acyltransferase Biochim Biophys Acta 2000 1529 245 56 Search in Google Scholar

[59] Schugar RC, Brown JM. Emerging roles of Flavin Monooxygenase 3 (FMO3) in cholesterol metabolism and atherosclerosis. Curr Opin Lipidol. 2015; 26:426–31. SchugarRC BrownJM Emerging roles of Flavin Monooxygenase 3 (FMO3) in cholesterol metabolism and atherosclerosis Curr Opin Lipidol 2015 26 426 31 Search in Google Scholar

[60] VanPatten S, Ranginani N, Shefer S, Nguyen LB, Rossetti L, Cohen DE. Impaired biliary lipid secretion in obese Zucker rats: leptin promotes hepatic cholesterol clearance. Am J Physiol Gastrointest Liver Physiol. 2001; 281:G393–404. VanPattenS RanginaniN SheferS NguyenLB RossettiL CohenDE Impaired biliary lipid secretion in obese Zucker rats: leptin promotes hepatic cholesterol clearance Am J Physiol Gastrointest Liver Physiol 2001 281 G393 404 Search in Google Scholar

[61] Li K, Liu Y, Venners SA, Hsu YH, Jiang S, Weinstock J, et al. Effects of LEP G2548A and LEPR Q223R polymorphisms on serum lipids and response to simvastatin treatment in Chinese patients with primary hyperlipidemia. Clin Appl Thromb Hemost. 2017; 23:336–44. LiK LiuY VennersSA HsuYH JiangS WeinstockJ Effects of LEP G2548A and LEPR Q223R polymorphisms on serum lipids and response to simvastatin treatment in Chinese patients with primary hyperlipidemia Clin Appl Thromb Hemost 2017 23 336 44 Search in Google Scholar

[62] Sun Y-M, Wang L-F, Li J, Li Z-Q, Pan W. The 223A>G polymorphism of the leptin receptor gene and lipid-lowering efficacy of simvastatin in Chinese patients with coronary heart disease. Eur J Clin Pharmacol. 2009; 65:157–61. SunY-M WangL-F LiJ LiZ-Q PanW The 223A>G polymorphism of the leptin receptor gene and lipid-lowering efficacy of simvastatin in Chinese patients with coronary heart disease Eur J Clin Pharmacol 2009 65 157 61 Search in Google Scholar

[63] Shunmoogam N, Naidoo P, Chilton R. Paraoxonase (PON)-1: a brief overview on genetics, structure, polymorphisms and clinical relevance. Vasc Health Risk Manag. 2018; 14:137–43. ShunmoogamN NaidooP ChiltonR Paraoxonase (PON)-1: a brief overview on genetics, structure, polymorphisms and clinical relevance Vasc Health Risk Manag 2018 14 137 43 Search in Google Scholar

[64] Fu R, Sun Y-M, Su Y, Wu Y, Luan Y. Effect of statin therapy on plasma high-density lipoprotein-cholesterol levels is modified by paraoxonase 1 in Chinese patients with coronary heart disease. Clin Exp Pharmacol Physiol. 2008; 35:982–3. FuR SunY-M SuY WuY LuanY Effect of statin therapy on plasma high-density lipoprotein-cholesterol levels is modified by paraoxonase 1 in Chinese patients with coronary heart disease Clin Exp Pharmacol Physiol 2008 35 982 3 Search in Google Scholar

[65] Meyer Zu Schwabedissen HE, Böttcher K, Chaudhry A, Kroemer HK, Schuetz EG, Kim RB. Liver X receptor α and farnesoid X receptor are major transcriptional regulators of OATP1B1. Hepatology. 2010; 52:1797–807. Meyer Zu SchwabedissenHE BöttcherK ChaudhryA KroemerHK SchuetzEG KimRB Liver X receptor α and farnesoid X receptor are major transcriptional regulators of OATP1B1 Hepatology 2010 52 1797 807 Search in Google Scholar

[66] Hu M, Lui SSH, Tam L-S, Li EK, Tomlinson B. The farnesoid X receptor-1G>T polymorphism influences the lipid response to rosuvastatin. J Lipid Res. 2012; 53:1384–9. HuM LuiSSH TamL-S LiEK TomlinsonB The farnesoid X receptor-1G>T polymorphism influences the lipid response to rosuvastatin J Lipid Res 2012 53 1384 9 Search in Google Scholar

[67] Rafeeq MM, Ahmad F, Rahman SZ, Siddiqi SS, Shakil S. Effect of an SNP in SCAP gene on lipid-lowering response to rosuvastatin in Indian patients with metabolic syndrome. Pharmacogenomics. 2016; 17:2015–24. RafeeqMM AhmadF RahmanSZ SiddiqiSS ShakilS Effect of an SNP in SCAP gene on lipid-lowering response to rosuvastatin in Indian patients with metabolic syndrome Pharmacogenomics 2016 17 2015 24 Search in Google Scholar

[68] Freeman GJ, Casasnovas JM, Umetsu DT, DeKruyff RH. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity. Immunol Rev. 2010; 235:172–89. FreemanGJ CasasnovasJM UmetsuDT DeKruyffRH TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity Immunol Rev 2010 235 172 89 Search in Google Scholar

[69] Zhang QH, Yin RX, Chen WX, Cao XL, Chen YM. Association between the TIMD4-HAVCR1 variants and serum lipid levels, coronary heart disease and ischemic stroke risk and atorvastatin lipid-lowering efficacy. Biosci Rep. 2018; 38:BSR20171058. doi: 10.1042/BSR20171058 ZhangQH YinRX ChenWX CaoXL ChenYM Association between the TIMD4-HAVCR1 variants and serum lipid levels, coronary heart disease and ischemic stroke risk and atorvastatin lipid-lowering efficacy Biosci Rep 2018 38 BSR20171058 10.1042/BSR20171058 Open DOISearch in Google Scholar

[70] Takahashi T, Takahashi K, Yamashina M, Maesawa C, Kajiwara T, Taneichi H, et al. Association of the TNF-α-C-857T polymorphism with resistance to the cholesterol-lowering effect of HMG-CoA reductase inhibitors in type 2 diabetic subjects. Diabetes Care. 2010; 33:463–6. TakahashiT TakahashiK YamashinaM MaesawaC KajiwaraT TaneichiH Association of the TNF-α-C-857T polymorphism with resistance to the cholesterol-lowering effect of HMG-CoA reductase inhibitors in type 2 diabetic subjects Diabetes Care 2010 33 463 6 Search in Google Scholar

[71] Xu Y, Wang Y, Zhi J, Qi L, Zhang T, Li X. Impact of matrix metalloproteinase 9 rs3918242 genetic variant on lipid-lowering efficacy of simvastatin therapy in Chinese patients with coronary heart disease. BMC Pharmacol Toxicol. 2017; 18:1–6. XuY WangY ZhiJ QiL ZhangT LiX Impact of matrix metalloproteinase 9 rs3918242 genetic variant on lipid-lowering efficacy of simvastatin therapy in Chinese patients with coronary heart disease BMC Pharmacol Toxicol 2017 18 1 6 Search in Google Scholar

[72] Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, Rieder MJ, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet. 2008; 40:189–97. KathiresanS MelanderO GuiducciC SurtiA BurttNP RiederMJ Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans Nat Genet 2008 40 189 97 Search in Google Scholar

[73] Tai ES, Sim XL, Ong TH, Wong TY, Saw SM, Aung T, et al. Polymorphisms at newly identified lipid-associated loci are Pharmacogenomics of statin in Asians associated with blood lipids and cardiovascular disease in an Asian Malay population. J Lipid Res. 2009; 50:514–20. TaiES SimXL OngTH WongTY SawSM AungT Polymorphisms at newly identified lipid-associated loci are Pharmacogenomics of statin in Asians associated with blood lipids and cardiovascular disease in an Asian Malay population J Lipid Res 2009 50 514 20 Search in Google Scholar

[74] Yan TT, Yin RX, Li Q, Huang P, Zeng XN, Huang KK, et al. Sex-specific association of rs16996148 SNP in the NCAN/CILP2/PBX4 and serum lipid levels in the Mulao and Han populations. Lipids Health Dis. 2011; 10:1–15. YanTT YinRX LiQ HuangP ZengXN HuangKK Sex-specific association of rs16996148 SNP in the NCAN/CILP2/PBX4 and serum lipid levels in the Mulao and Han populations Lipids Health Dis 2011 10 1 15 Search in Google Scholar

[75] Paradis ME, Lamarche B. Endothelial lipase: its role in cardiovascular disease. Can J Cardiol. 2006; 22:31B–4B. ParadisME LamarcheB Endothelial lipase: its role in cardiovascular disease Can J Cardiol 2006 22 31B 4B Search in Google Scholar

[76] Cai G, Zhang B, Shi G, Weng W, Yang L, Xue S. Endothelial lipase genetic polymorphisms and the lipid-lowering response in patients with coronary artery disease on rosuvastatin. Lipids Health Dis. 2016; 15:1–6. CaiG ZhangB ShiG WengW YangL XueS Endothelial lipase genetic polymorphisms and the lipid-lowering response in patients with coronary artery disease on rosuvastatin Lipids Health Dis 2016 15 1 6 Search in Google Scholar

[77] Jiang S, Venners SA, Li K, Hsu Y-H, Weinstock J, Zou Y, et al. Effect modification by region in the associations of LEP G2548A and LEPR Q223R polymorphisms with statin-induced CK elevation. Oncotarget. 2017; 8:107565–76. JiangS VennersSA LiK HsuY-H WeinstockJ ZouY Effect modification by region in the associations of LEP G2548A and LEPR Q223R polymorphisms with statin-induced CK elevation Oncotarget 2017 8 107565 76 Search in Google Scholar

[78] Sai K, Kajinami K, Akao H, Iwadare M, Sato-Ishida R, Kawai Y, et al. A possible role for HLA-DRB1^*04:06 in statin-related myopathy in Japanese patients. Drug Metab Pharmacokinet. 2016; 31:467–70. SaiK KajinamiK AkaoH IwadareM Sato-IshidaR KawaiY A possible role for HLA-DRB1^*04:06 in statin-related myopathy in Japanese patients Drug Metab Pharmacokinet 2016 31 467 70 Search in Google Scholar

[79] Liu J-E, Liu X-Y, Chen S, Zhang Y, Cai L-Y, Yang M, et al. SLCO1B1 521T>C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case–control study. Eur J Clin Pharmacol. 2017; 73:1409–16. LiuJ-E LiuX-Y ChenS ZhangY CaiL-Y YangM SLCO1B1 521T>C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case–control study Eur J Clin Pharmacol 2017 73 1409 16 Search in Google Scholar

[80] Zhong Z, Wu H, Li B, Li C, Liu Z, Yang M, et al. Analysis of SLCO 1B1 and APOE genetic polymorphisms in a large ethnic Hakka population in southern China. J Clin Lab Anal. 2018; 32:e22408. doi: 10.1002/jcla.22408 ZhongZ WuH LiB LiC LiuZ YangM Analysis of SLCO 1B1 and APOE genetic polymorphisms in a large ethnic Hakka population in southern China J Clin Lab Anal 2018 32 e22408 10.1002/jcla.22408 Open DOISearch in Google Scholar

[81] Mammen AL, Gaudet D, Brisson D, Christopher-Stine L, Lloyd TE, Leffell MS, et al. Increased frequency of DRB1^*11:01 in anti–hydroxymethylglutaryl-coenzyme A reductase–associated autoimmune myopathy. Arthritis Care Res. 2012; 64:1233–7. MammenAL GaudetD BrissonD Christopher-StineL LloydTE LeffellMS Increased frequency of DRB1^*11:01 in anti–hydroxymethylglutaryl-coenzyme A reductase–associated autoimmune myopathy Arthritis Care Res 2012 64 1233 7 Search in Google Scholar

[82] Suarez-Kurtz G. Ethnic differences in drug therapy: a pharmacogenomics perspective. Expert Rev Clin Pharmacol. 2008; 1:337–9. Suarez-KurtzG Ethnic differences in drug therapy: a pharmacogenomics perspective Expert Rev Clin Pharmacol 2008 1 337 9 Search in Google Scholar

[83] Ho WF, Koo SH, Yee JY, Lee EJD. Genetic variations of the SLCO1B1 gene in the Chinese, Malay and Indian populations of Singapore. Drug Metab Pharmacokinet. 2008; 23:476–82. HoWF KooSH YeeJY LeeEJD Genetic variations of the SLCO1B1 gene in the Chinese, Malay and Indian populations of Singapore Drug Metab Pharmacokinet 2008 23 476 82 Search in Google Scholar

[84] Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, et al. The SLCO1B1^*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009; 54:1609–16. VooraD ShahSH SpasojevicI AliS ReedCR SalisburyBA The SLCO1B1^*5 genetic variant is associated with statin-induced side effects J Am Coll Cardiol 2009 54 1609 16 Search in Google Scholar

[85] SEARCH Study Collaborative Group; Bowman L, Armitage J, Bulbulia R, Parish S, Collins R. Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors. Am Heart J. 2007; 154:815–23, 823.e1–6. SEARCH Study Collaborative Group BowmanL ArmitageJ BulbuliaR ParishS CollinsR Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors Am Heart J 2007 154 815 23 823.e1 6 Search in Google Scholar

[86] Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D, et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther. 2012; 92:112–7. WilkeRA RamseyLB JohnsonSG MaxwellWD McLeodHL VooraD The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy Clin Pharmacol Ther 2012 92 112 7 Search in Google Scholar

[87] Ramakumari N, Indumathi B, Katkam SK, Kutala VK. Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects. Indian Heart J. 2018; 70:S120–5. RamakumariN IndumathiB KatkamSK KutalaVK Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects Indian Heart J 2018 70 S120 5 Search in Google Scholar

[88] C. Thambiah S, Meor Anuar Shuhaili MFR, Chew BH, Samsudin IN, Abdul Rahman H, Stanslas J, et al. A pilot study on the association between SLCO1B1 RS4363657 polymorphism and muscle adverse events in adults with newly diagnosed dyslipidaemia who were prescribed a statin: the Malaysian primary health care cohort. Biomarkers. 2019; 24:659–65. C. ThambiahS Meor Anuar ShuhailiMFR ChewBH SamsudinIN Abdul RahmanH StanslasJ A pilot study on the association between SLCO1B1 RS4363657 polymorphism and muscle adverse events in adults with newly diagnosed dyslipidaemia who were prescribed a statin: the Malaysian primary health care cohort Biomarkers 2019 24 659 65 Search in Google Scholar

[89] Food and Drug Administration. Crestor (rosuvastatin calicum) prescribing information. Washington (DC): FDA; 2015. Food and Drug Administration Crestor (rosuvastatin calicum) prescribing information Washington (DC) FDA 2015 Search in Google Scholar

[90] Wu H-F, Hristeva N, Chang J, Liang X, Li R, Frassetto L, et al. Rosuvastatin pharmacokinetics in Asian and white Subjects wild type for both OATP1B1 and BCRP under control and inhibited conditions. J Pharma Sci. 2017; 106:2751–7. WuH-F HristevaN ChangJ LiangX LiR FrassettoL Rosuvastatin pharmacokinetics in Asian and white Subjects wild type for both OATP1B1 and BCRP under control and inhibited conditions J Pharma Sci 2017 106 2751 7 Search in Google Scholar

[91] Arrigoni E, Del Re M, Fidilio L, Fogli S, Danesi R, Di Paolo A. Pharmacogenetic foundations of therapeutic efficacy and adverse events of statins. Int J Mol Sci. 2017; 18:104. doi: 10.3390/ijms18010104 ArrigoniE Del ReM FidilioL FogliS DanesiR Di PaoloA Pharmacogenetic foundations of therapeutic efficacy and adverse events of statins Int J Mol Sci 2017 18 104 10.3390/ijms18010104 Open DOISearch in Google Scholar